Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 52.34 USD 0.75%
Market Cap: 106.6B USD

Bristol-Myers Squibb Co
Interest Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bristol-Myers Squibb Co
Interest Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Expense CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Interest Expense
$2B
CAGR 3-Years
16%
CAGR 5-Years
8%
CAGR 10-Years
26%
Johnson & Johnson
NYSE:JNJ
Interest Expense
$894m
CAGR 3-Years
78%
CAGR 5-Years
35%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Expense
$1.3B
CAGR 3-Years
11%
CAGR 5-Years
9%
CAGR 10-Years
7%
Zoetis Inc
NYSE:ZTS
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Interest Expense
$897m
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
19%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
72.37 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Interest Expense?
Interest Expense
2B USD

Based on the financial report for Sep 30, 2025, Bristol-Myers Squibb Co's Interest Expense amounts to 2B USD.

What is Bristol-Myers Squibb Co's Interest Expense growth rate?
Interest Expense CAGR 10Y
26%

Over the last year, the Interest Expense growth was 11%. The average annual Interest Expense growth rates for Bristol-Myers Squibb Co have been 16% over the past three years , 8% over the past five years , and 26% over the past ten years .

Back to Top